EUVIMEDEUVIMED entdecken
Open Access

Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis

A Stoltz, R R Nathavitharana iD, E de Kock iD, V Ueckermann iD, P Jensen, C M Mendel, M Spigelman, E A Nardell iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von A Stoltz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University of Pretoria School of Medicine, Pretoria, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human–guinea pig (H-GP) transmission model.

Methods

In experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period.

Results

In experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P > .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P < .0001).

Conclusions

In this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantAntitubercular AgentsGuinea PigsAnimalsHumansDiarylquinolinesLinezolidFemaleMaleNitroimidazolesAdultMiddle AgedMycobacterium tuberculosisTuberculin Test

Stichwörter der Autor:innen

drug-resistant tuberculosisearly transmission impacttransmissiontuberculosistuberculosis treatment

Substanzen

Antitubercular AgentsbedaquilineDiarylquinolinesLinezolidpretomanidNitroimidazoles

Autor:innen und Institutionen

  • Department of Infectious Diseases, University of Pretoria School of Medicine, Pretoria, South Africa.
  • Division of Infectious Diseases, Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.
  • Retrasol, Pretoria, South Africa.
  • Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Global Alliance for TB Drug Development, New York, New York, USA.
  • Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: R R Nathavitharana, E de Kock, V Ueckermann, E A Nardell

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Stoltz, A., Nathavitharana, R. R., de Kock, E., Ueckermann, V., Jensen, P., Mendel, C. M., Spigelman, M., & Nardell, E. A. (2025). Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf005

Vancouver

Stoltz A, Nathavitharana RR, de Kock E, Ueckermann V, Jensen P, Mendel CM, et al. Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf005

BibTeX
@article{Stoltz2025,
  author = {Stoltz, A and Nathavitharana, R R and de Kock, E and Ueckermann, V and Jensen, P and Mendel, C M and Spigelman, M and Nardell, E A},
  title = {Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf005}
}
Kostenlos starten →